<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;table border="1" cellspacing="0" summary="meeting date, time, location and sponsoring Center" width="98%"&gt;&lt;tbody&gt;&lt;tr valign="top" align="left" bgcolor="#cccccc"&gt;&lt;th&gt;Center&lt;/th&gt;&lt;th&gt;Date&lt;/th&gt;&lt;th&gt;Time&lt;/th&gt;&lt;th&gt;Location&lt;/th&gt;&lt;/tr&gt;&lt;tr valign="top" align="left"&gt;&lt;td&gt;CBER&lt;/td&gt;&lt;td&gt;February 18-19, 2009&lt;/td&gt;&lt;td&gt;February 18, 2009 from 8:30 a.m. to approximately 5:30 p.m.&lt;br /&gt;February 19, 2009 from 8:30 a.m. to approximately 4:00 p.m.&lt;/td&gt;&lt;td&gt;Hilton Washington DC/ Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910.&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;h3&gt;Agenda&lt;/h3&gt;&lt;p&gt;On February 18, 2009, in the morning, the committee will discuss and make recommendations on the selection of strains to be included in the influenza virus vaccine for the 2009 - 2010 influenza season , and in the afternoon will discuss the utility of adding a second B strain to current seasonal influenza vaccines. On February 19, 2009, the committee will discuss the conducting of clinical studies of pandemic influenza vaccine in the pediatric population in the absence of an influenza pandemic.&lt;/p&gt;&lt;h3&gt;&lt;a href="[!--$ssLink(&amp;quot;ucm129568.htm&amp;quot;)--]"&gt;Meeting Materials&lt;/a&gt;&lt;/h3&gt;&lt;h3&gt;Public Participation Information&lt;/h3&gt;&lt;p&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Written submissions may be made to the contact person on or before February 12, 2009 .&lt;/li&gt;&lt;li&gt;Oral presentations from the public will be scheduled between approximately 1:15 p.m. and 1:45 p.m. on February 18, 2009, and between approximately 1:30 p.m. and 2:00 p.m. on February 19, 2009. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of propose d participants, and an indication of the approximate time requested to make their presentations on or before February 9, 2009. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by February 10, 2009 .&lt;/li&gt;&lt;/ul&gt;&lt;h3&gt;Contact Information&lt;/h3&gt;&lt;ul&gt;&lt;li&gt;Christine Walsh, R.N.&lt;br /&gt;1402 Rockville Pike, HFM-71, Rockville, MD 20852&lt;br /&gt;301-827-0314&lt;br /&gt;FAX: 301-827-0294&lt;br /&gt;e-mail: &lt;a href="mailto:Christine.Walsh@fda.hhs.gov"&gt;Christine.Walsh@fda.hhs.gov&lt;/a&gt;&lt;/li&gt;&lt;li&gt;FDA Advisory Committee Information Line&lt;br /&gt;1-800-741-8138&lt;br /&gt;(301-443-0572 in the Washington, DC, area)&lt;br /&gt;code 3014512391&lt;br /&gt;Please call the Information Line for up-to-date information on this meeting.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting.&lt;/p&gt;&lt;p&gt;A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency's Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.&lt;/p&gt;&lt;p&gt;Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Christine Walsh or Denise Royster at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please &lt;a href="[!--$ssNodeLink(&amp;quot;1840&amp;quot;)--]"&gt;visit our Web site&lt;/a&gt; for procedures on public conduct during advisory committee meetings.&lt;/p&gt;&lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
